HeartSciences Inc (HSCS) Q1 2026 Earnings Report

Comprehensive analysis of HeartSciences Inc's financial performance for Q1 2026 with historical comparisons and future outlook.

Previous: Q3 2025
HeartSciences Inc
HSCS
$2.93 -0.20%
Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Devices
Q1 2026
Published: Sep 11, 2025

Earnings Highlights

  • Revenue of $1.90M up 0% year-over-year
  • EPS of $-1.58 increased by 42.1% from previous year
  • Gross margin of 60.0%
  • Net income of -2.05M
  • "N/A" - N/A

HeartSciences Inc (HSCS) QQ1 2026 Results – AI-Enhanced ECG Platform Advancement Amid Heavy R&D Investment

Executive Summary

HeartSciences Inc (HSCS) reported QQ1 2026 results with modest revenue of USD 1.9 million, producing a gross profit of USD 1.14 million and a robust gross margin of 60.0%. However, the quarter was dominated by extraordinary research and development expenditure (USD 997.206 million) and substantial selling, general, and administrative spending (USD 878.053 million), which together drove operating expenses to USD 1.875 billion and yielded a substantial operating loss. Net income for the period stood at USD -2.055 million, with an EPS of USD -1.58, underscoring a pronounced burn driven by pre-commercial investment in AI-enabled ECG technology and cloud-based platforms.

Key Performance Indicators

Revenue

1.90M
QoQ: N/A | YoY:N/A

Gross Profit

1.14M
60.00% margin
QoQ: N/A | YoY:12 489.96%

Operating Income

-1.87B
QoQ: 20.97% | YoY:-99 598.32%

Net Income

-2.05M
QoQ: 99.92% | YoY:-11.31%

EPS

-1.58
QoQ: 99.94% | YoY:42.12%

Revenue Trend

Margin Analysis

Key Insights

Revenue: USD 1,900,000; Cost of Revenue: USD 760,000; Gross Profit: USD 1,140,000; Gross Margin: 60.0%; Research and Development Expenses: USD 997,206,000; Selling, General and Administrative Expenses: USD 878,053,000; Operating Expenses: USD 1,875,259,000; EBITDA: USD -1,839,631; EBITDA Margin: -96.8%; Operating Income: USD -1,874,119,000; Operating Income Margin: -986.38%; Total Other Income/Expenses: USD -180,875,000; Income Before Tax: USD -2,054,994,000; Net Income: USD -2,054,994; Net Inco...

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 1.90 -1.58 +0.0% View
Q3 2025 0.00 -2,572.16 +0.0% View
Q2 2025 0.00 -2.27 +0.0% View
Q1 2025 0.00 -2.64 +0.0% View
Q4 2024 0.00 -2.73 +0.0% View

More HSCS Quarterly Reports

HSCS

HeartSciences Inc
Q3 2025 Report
HeartSciences Inc (HSCS) QQ3 2025 Results Analysis – AI-ECG Platform Progress Underpins Long-Term Growth Amid Substantial Near-Term Losses...
Read full report

HSCS

HeartSciences Inc
Q2 2025 Report
HeartSciences Inc (HSCS) QQ2 2025 Results Analysis: AI-Enhanced ECG Technology in Early-Stage Medical Devices...
Read full report

HSCS

HeartSciences Inc
Q1 2025 Report
HeartSciences Inc (HSCS) QQ1 2025 Results Analysis — Early-Stage AI-ECG Platform Investment Drives R&D Burn with No Near-Term Revenue...
Read full report

HSCS

HeartSciences Inc
Q4 2024 Report
HeartSciences Inc (HSCS) QQ4 2024 Results – AI-ECG Innovation in Early Commercial Phase: Revenue Still Elusive, Large R&D Investment Sustains Progre...
Read full report

Q1 2026 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

View more companies and financial data in the Healthcare sector.

Explore Sector

HSCS Full Profile

View complete financial profile, news, and analysis for HeartSciences Inc.

Company Profile

HSCS Financial Statements

Access detailed balance sheets, income statements, and cash flow reports.

View Financials

Earnings Calendar

Stay updated with upcoming earnings announcements from all public companies.

View Calendar